Biologics

BoneSupport Launches Next Generation of Cerament® G

6-30-2023 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces the launch of the next generation of the company’s breakthrough antibiotic-eluting bone graft substitute, CERAMENT G. Improvements to CERAMENT G have been made to increase ease of use and to reduce environmental impact.

The same composition, mechanism of action, and clinical results as previous versions of CERAMENT G apply, but all components in the kit are now surface sterile. In addition, the shelf life of the product has been extended by one year, to a total of three years. The improvements create a better workflow during surgery leading to increased ease of use and user efficiency. Furthermore, the physical dimensions of the new CERAMENT G kit are 28% smaller than before with packaging material reduced by 35%. The kit improvements were made after extensive consultation with customers.

“Surgical teams value that CERAMENT G comes in an all-in-one kit and this latest update offers greater efficiency in the operating room. At same time, the product’s reduced packaging waste is a step forward in our corporate sustainability objectives,” said Emil Billbäck, CEO of BONESUPPORT.

The next generation of CERAMENT G is first released in Europe and then in other markets over the coming months.

For more information contact:

BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 329 million in 2022. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Josh Sandberg

Josh Sandberg is the President and CEO of Ortho Spine Partners and sits on several company and industry related Boards. He also is the Creator and Editor of OrthoSpineNews.

Related Articles

Back to top button